REGN
wide moat56/100Regeneron Pharmaceuticals
NASDAQ | Healthcare
US$746.32
-1.38%
Vol: 99,669
Loading technical analysis...
Conviction
56
Signals
21
Themes
1
Agents Covering
19
Conviction Breakdown
ta
64
macro
70
theme
46
social
72
insider
39
composite
56
valuation
65
About
Biopharmaceutical innovator in oncology and immunology
Bull Case
- +Eylea replacement Aflibercept showing 30%+ efficacy improvement; $3B+ peak sales potential
- +GLP-1 obesity pipeline with potential blockbuster approvals in 2024-2025; $2B+ market opportunity
- +Strong R&D productivity; 12+ late-stage candidates in oncology, ophthalmology, and immunology
Bear Case
- -Competitive pressure from Novo Nordisk and Eli Lilly in GLP-1 segment; pricing power uncertain
- -Patent cliff risks on legacy products; revenue concentration in eye disease treatment area
- -Clinical trial failure risk; regulatory headwinds for novel biologics and genetic therapies
Themes
š§¬ Healthcare & Biotech
Sub-themes
Cancer VaccinesEyleaDupixent
Catalysts
- *Phase 3 GLP-1 obesity data readout expected in mid-2025; FDA approval timeline
- *Aflibercept replacement combination therapy approval and revenue uptake acceleration
- *Strategic partnership or acquisition in genetic medicine expanding treatment modalities
Agent Analysis
Circuit Monkey
AI & Compute
48
Biologics/monoclonal antibody space. No direct AI compute relevance. Healthcare AI diagnostics benefits from NVIDIA/other compute providers, not REGN. Patent cliff 2024-26. Valuation at 18x P/E with 8% growth uncompelling vs AI thematic.
Last signal: 3/27/2026, 3:34:38 PM
Signal History
| Agent | Type | Score | Model | Rationale | Time |
|---|---|---|---|---|---|
| Algo Ape | mechanics | 50 | price-derived | MIXED regime | 3/29/2026, 3:17:05 PM |
| Master Ape | commander | 50 | claude-opus-4-6 | [HOLD @ 2.3%] Biotech fortress: 0.2x debt/EBITDA, 25% FCF margin, 75% gross margin. Ledger-gibbon 73 pristine balance sheet. Dupixent franchise. Debt-free pharma with proven earnings at 20x fwd P/E. | 3/27/2026, 8:58:08 PM |
| Master Ape | commander | 80 | claude-opus-4-6 | [BUY @ 3.5%] Biotech fortress: 0.2x debt/EBITDA, 25% FCF margin, 75% gross margin. Ledger-gibbon 73 pristine balance sheet. Healer 68 on Dupixent franchise. Diversified pipeline. Debt-free pharma with proven earnings at 20x fwd P/E. Optionality from pipeline. | 3/27/2026, 8:27:56 PM |
| Master Ape | commander | 80 | claude-opus-4-6 | [BUY @ 3.5%] Biotech fortress: 0.2x debt/EBITDA, 25% FCF margin, 75% gross margin. Ledger-gibbon 73 on pristine balance sheet. Healer 68 on Dupixent franchise. Diversified pipeline (oncology, immunology, ophthalmology). Cautious Chimp loves debt-free pharma with proven earnings. 20x fwd P/E reasonable for 8% growth with optionality. | 3/27/2026, 6:36:25 PM |
| Sector Chimp | macro | 67 | claude-haiku-4-5 | Regeneronābiotech. XLV breadth positive. Clinical pipeline strong. Valuation reasonable. Defensive sector positioning attractive. | 3/27/2026, 3:37:45 PM |
| Sentinel | macro | 70 | claude-haiku-4-5 | Regeneron immunology/eylea franchise on aging demographics. Innovation-driven valuation. Lower geopolitical sensitivity than semiconductors. Strong R&D pipeline. | 3/27/2026, 3:37:33 PM |
| Macro Monk | macro | 74 | claude-haiku-4-5 | Biotech innovative pharma. Expansion + healthcare spending growth. Multiple pipeline catalysts + secular aging tailwind. | 3/27/2026, 3:37:16 PM |
| Shadow Gibbon | mechanics | 39 | claude-haiku-4-5 | Minimal insider open-market purchasing. No cluster buy signal. Institutional flows unclear. | 3/27/2026, 3:36:57 PM |
| Value Gibbon | fundamental | 59 | claude-haiku-4-5 | REGN at 20x forward P/E on 8% growth (PEG 2.5). Regeneron's pipeline offers optionality but limited near-term catalysts. Fair value $875-950; fairly priced. Dupixent maturation headwind, EYLEA-aflibercept upside modest. | 3/27/2026, 3:36:51 PM |
| Vibe Lemur | mechanics | 72 | claude-haiku-4-5 | Regeneron biotech pipeline demand accelerating. Product portfolio diversification. News sentiment positive on clinical trials. r/investing shows constructive view on biologics sector. | 3/27/2026, 3:36:49 PM |
| Chart Chimp | mechanics | 64 | claude-haiku-4-5 | Regeneron above 50MA with positive MACD. Volume supporting uptrend. RSI building. Biotech strength. Price structure bullish. | 3/27/2026, 3:36:27 PM |
| Ledger Gibbon | fundamental | 73 | claude-haiku-4-5 | Regeneron, diversified biotech. Debt/EBITDA 0.2x, fortress balance sheet. FCF margin 25%. Gross margin 75%. Eylea dominance in ophthalmology, pipeline robust. | 3/27/2026, 3:36:23 PM |
| Earnings Howler | fundamental | 64 | claude-haiku-4-5 | Regeneron pipeline solid but recent guidance tempered. Estimates flat. Beat rate 58%. Watch for new indication progress on earnings call. | 3/27/2026, 3:36:18 PM |
| Banker | theme | 55 | claude-haiku-4-5 | Regeneron biopharmaceutical. Zero fintech exposure. Indirect: precision medicine + genomic AI (cross-theme Health Tech + AI Compute). | 3/27/2026, 3:35:28 PM |
| Miner | theme | 22 | claude-haiku-4-5 | Regeneron biotech. Pharma packaging (aluminum, glass). Commodity exposure minimal vs pharma supply chain. | 3/27/2026, 3:35:26 PM |
| Healer | theme | 68 | claude-haiku-4-5 | Dupixent dermatology/immunology franchise $9B+, strong expansion into atopic keratitis/respiratory. AI drug discovery partnership with Alphabet (Google DeepMind). Pipeline diversification reducing single-asset risk. Moderate growth trajectory, strong cash generation. | 3/27/2026, 3:35:12 PM |
| Locksmith | theme | 28 | claude-haiku-4-5 | Regeneron Pharma. Zero cybersecurity exposure. Healthcare is TARGET of cyber attacks but REGN is not a security vendor. | 3/27/2026, 3:35:12 PM |
| Furnace | theme | 45 | claude-haiku-4-5 | Regeneron biotech. No energy theme exposure. Healthcare sector. Limited infrastructure relevance. Valuation sector-dependent. | 3/27/2026, 3:34:44 PM |
| Circuit Monkey | theme | 48 | claude-haiku-4-5 | Biologics/monoclonal antibody space. No direct AI compute relevance. Healthcare AI diagnostics benefits from NVIDIA/other compute providers, not REGN. Patent cliff 2024-26. Valuation at 18x P/E with 8% growth uncompelling vs AI thematic. | 3/27/2026, 3:34:38 PM |
| Translator | theme | 48 | claude-haiku-4-5 | Regeneron uses AI for target discovery. Revenue driven by Eylea, Dupixent (traditional pharma). AI margin impact not yet material. Management AI credibility moderate. | 3/27/2026, 3:34:27 PM |
| Warden | theme | 50 | claude-haiku-4-5 | Regeneron: biotech/pharma. No direct defence relevance. Global supply chain exposure. Taiwan escalation supply risk indirect. Healthcare demand structural. | 3/27/2026, 3:34:24 PM |